ARCT

Over the past six months, Arcturus Therapeutics' stock was impacted by several events. In August 2026, the company reported Q2 earnings, beating analyst expectations with an EPS of -$0.84, leading to a 21.9% stock gain. On the same day, Arcturus regained global rights to its KOSTAIVE® vaccine and broader infectious disease portfolio, resolving an arbitration and receiving a $12 million cash payment while being released from approximately $16 million in R&D credit liabilities. In September 2026, the company presented positive Phase 2 clinical data for its ARCT-810 program for OTC deficiency and provided an update on its mRNA liver therapeutics platform. Following this, Citi upgraded Arcturus, and the stock rallied due to positive liver disease study data and a broader sector lift from a Moderna cancer win. Arcturus further highlighted its ARCT-810 Phase II data and unveiled its next-generation OTC therapy platform. Towards the end of September, Zacks Investment Research published positive news about RNA therapeutics stocks, including ARCT. In October 2026, news on Stocktwits mentioned ARCT rallying after a Russia plague lab worker's death, with retail traders anticipating 'contract awards'.